- Home
- KLAC vs SCLXW Comparison
KLAC vs SCLXW Comparison
Compare KLAC & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLAC
- SCLXW
- Stock Information
- Founded
- KLAC 1975
- SCLXW N/A
- Country
- KLAC United States
- SCLXW United States
- Employees
- KLAC N/A
- SCLXW 117
- Industry
- KLAC Electronic Components
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- KLAC Technology
- SCLXW Health Care
- Exchange
- KLAC Nasdaq
- SCLXW Nasdaq
- Market Cap
- KLAC N/A
- SCLXW N/A
- IPO Year
- KLAC N/A
- SCLXW N/A
- Fundamental
- Price
- KLAC $580.11
- SCLXW $0.11
- Analyst Decision
- KLAC Buy
- SCLXW
- Analyst Count
- KLAC 20
- SCLXW 0
- Target Price
- KLAC $832.60
- SCLXW N/A
- AVG Volume (30 Days)
- KLAC 951.5K
- SCLXW 4.0K
- Earning Date
- KLAC 04-24-2025
- SCLXW 03-07-2025
- Dividend Yield
- KLAC 1.09%
- SCLXW N/A
- EPS Growth
- KLAC 20.61
- SCLXW N/A
- EPS
- KLAC 23.75
- SCLXW N/A
- Revenue
- KLAC $10,846,957,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- KLAC $23.97
- SCLXW N/A
- Revenue Next Year
- KLAC $3.84
- SCLXW N/A
- P/E Ratio
- KLAC $26.14
- SCLXW N/A
- Revenue Growth
- KLAC 12.15
- SCLXW 22.02
- 52 Week Low
- KLAC $609.40
- SCLXW $0.18
- 52 Week High
- KLAC $896.32
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- KLAC 26.32
- SCLXW N/A
- Support Level
- KLAC $655.42
- SCLXW N/A
- Resistance Level
- KLAC $695.62
- SCLXW N/A
- Average True Range (ATR)
- KLAC 21.08
- SCLXW 0.00
- MACD
- KLAC -10.37
- SCLXW 0.00
- Stochastic Oscillator
- KLAC 3.74
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.